Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 113 Neoplasm Metastasis 5 Carcinoma, Intraductal, Noninfiltrating 5 Polycystic Ovary Syndrome 4 Ovarian Neoplasms 4 Osteoporosis 4 Neoplasms 4 Infertility 4 Breast Neoplasms, Male 4 Arthralgia 4 Fallopian Tube Neoplasms 3 Triple Negative Breast Neoplasms 2 Pain 2 Leiomyosarcoma 2 Leiomyoma 2 Endometrial Neoplasms 2 Cystadenocarcinoma, Serous 2 Breast Carcinoma In Situ 2 Bone Diseases, Metabolic 2 Advanced Breast Cancer 2 Uterine Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Cysts 1 Osteitis Deformans 1 Obesity 1 Multiple Endocrine Neoplasia Type 1 1 Medullary cystic kidney disease 1 1 Lymphoma, Non-Hodgkin 1

Interventions

Sirolimus 5 Everolimus 4 carbon-11 acetate 1 Sugars 1 Simvastatin 1 Resveratrol 1 Octreotide 1 Letrozole 1 Imatinib Mesylate 1 Hydroxychloroquine 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Lymphangioleiomyomatosis × Letrozole × Clear all

NCT01353209 2024-04-17

TRAIL

University of Cincinnati

Phase 2 Completed

17 enrolled 13 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡